2020–2021 BCSC Basic and Clinical Science Course™
1 Update on General Medicine
Chapter 11: Behavioral and Neurologic Disorders
Highlights
-
Each year, 1 in 5 adults is affected with a mental health disorder, of which only half are ever diagnosed by a physician.
-
Newer therapeutic agents for psychiatric diseases allow for more effective treatment with generally fewer adverse effects compared with older agents.
-
Visual impairment almost doubles the risk of acquired depression.
-
Second-generation antipsychotics (SGAs) such as olanzapine, quetiapine, and clozapine may be associated with the onset or worsening of diabetes mellitus and its associated ocular findings.
-
The use of the antiepileptic medication vigabatrin is associated with irreversible and often asymptomatic concentric visual field loss in up to 50% of patients.
-
Some new treatments for Parkinson disease may be neuroprotective and are therefore considered potential disease-modifying agents.
Excerpted from BCSC 2020-2021 series: Section 1 - Update on General Medicine. For more information and to purchase the entire series, please visit https://www.aao.org/bcsc.